Ryan B. Chirnomas
Partner
Email: rchirnomas@whda.com
Add to my contacts

プロファイル（日本語）

B.S. Molecular and Cellular Biology (University of Arizona, 2000); cum laude

J.D. (American University, Washington College of Law, 2005)

M.S. Biotechnology (Johns Hopkins University, expected 2013)

Admitted to practice before the U.S. Patent and Trademark Office, 2005

Admitted to bar (Virginia, 2005 and District of Columbia, 2007)

Prior Affiliation:
Glushko-Samuelson Intellectual Property Law Clinic, Washington College of Law, American University

Dr. Volker Vossius Patentanwaltskanzlei/Rechtsandwaltskanzlei, Munich, Germany

Laboratory of Mammary Gland Biology, University of Arizona

Author:
Classen v. Biogen: CAFC tries to target patent eligibility but misses, Patent Law Practice Center (2011)

AMP v. U.S.P.T.O.: Myriad wins the battle, but will the war continue? Patent Law Practice Center (2011)

AMP v. U.S.P.T.O.: Oral Argument at the Federal Circuit, Patent Law Practice Center (2011)

Co-Author:
“Are Genes Patent-Eligible Subject Matter?  The Myriad Case.” Pharmstage, 2011.

Brief of amicus curiae on behalf of Public Knowledge in Knorr-Bremse v. Dana Corp., filed with the Federal Circuit Court of Appeals, 2003.

"Activation of the aromatic hydrocarbon receptor pathway is not sufficient for transcriptional repression of BRCA-1: Requirements for metabolism of benzo[a]pyrene to 7r,8t-dihydroxy-9t, 10-epoxy-7,8,9,20-tetrahydrobenzo[a]pyrene." Cancer Research, 2002.

"Epigenetics of breast cancer: Polycyclic aromatic hydrocarbons as risk factors." Environmental and Molecular Mutagenesis, 2002.

"Deoxycholate, an endogenous tumor promoter and DNA damaging agent, modulates BRCA-1 expression in apoptosis-sensitive epithelial cells: Loss of BRCA-1 Expression in colonic adenocarcinomas." Nutrition and Cancer, 2003.

Lectures:
“Recent Developments in U.S. Biotech Patent Law 2011” Japan Patent Attorney Association, Bio-Pharma Study Group, Tokyo, Japan, 2011.

“Gene Patenting:  The Myriad Genetics Case” Japan Patent Attorney Association, Bio-Pharma Study Group, Tokyo, Japan, 2010.

“Expedited Examination” Japan Intellectual Property Association, Washington, D.C., 2009

“Recent CAFC Decisions” Japan Intellectual Property Association, Tokyo, Japan, 2007.

Representative Technologies and Specialties:
Biological arts, in particular, gene therapy and other therapeutic methods, medical devices, cancer biology, microscopy, microarray/biochip assay systems, transgenic animals, screening methods, diagnostic methods, and artificial bone technologies; mechanical arts, in particular, general automotive technologies, hybrid vehicle systems, vibration isolation, and clean room equipment; internet and business method technologies.